David Durantel
  • E-mail :[email]
  • Phone : +33 4 72 68 19 91
  • Location : Lyon, France
Last update 2018-09-21 11:04:09.461

David Durantel Molecular and Cellular Virologist, PhD, HDR

Course and current status

I obtained my PhD at the University of Montpellier in 1997. After three postdoctoral trainings respectively at Oxford Brookes University (UK), University of Oxford, and at INSERM-U271, I obtained a tenure position at INSERM in 2005, my Habilitation in 2008 from the University of Lyon (UCBL), and was recently promoted Director of Research at INSERM.

I currently head a team at the Cancer Research Center of Lyon (CRCL, INSERM-U1052) in France on a program of research aiming at better understanding the interplay between HBV/HDV and liver innate immunity in order to contribute to the development of novel host-targeting agents, in particular immune-therapeutics.

I have been involved in the past on several research projects related to drug discovery, in particular research on HCV/HBV morphogenesis inhibitors, research on PRR agonists as potential adjuvant for immune-therapeutic concepts, as well as to antiviral resistance.

I have authored/co-authored 95 PubMed-recorded publications, as well as numerous reviews/editorials, proceedings and book chapters. I act as reviewers for many journals, including Gastroenterology, Gut, Hepatology, J. Hepatol, Plos-Pathogen, etc…

Since 2014, I am senior Editor for the Antiviral Research journal, section viral hepatitis.

I have been a member of the Executive Board of AFEF (French association for liver research) between 2015 and 2018. I widely contribute to national coordination on HCV/HBV/HDV/HIV research at ANRS by being a member of the study section committee (SSC)-12 (viral hepatitis), in the Executive Board of the concerted action (CA)-41 (basic science on HIV/host interactions), as well as a member of CA-42 (host-virus interactions).

Scientific summary

I currently head a team of 15-20 people working on the understanding of the interplay between the 2 hepatotropic oncoviruses HBV and HDV and liver innate immunity in order to identify host-factors that could be targeted for antiviral and anticancerous therapeutic strategies. We work on the development of those host targeting agents (HTA) from early stage to preclinical devopment using relevant mouse models we contibuted to develop and characterise. Some HTA can have a combined antiviral and anticancerous properties this defining what we call HTAC.

Our ultimate goal is to team-up with industrial partners or spin-off an activity to move forward an HTA or an HTAC to the clinic and improved upon current therapies against chronic viral hepatitis and related liver diseases.

Setected recent publications:

1. T. Lahlali, J. M. Berke, K. Vergauwen, A. Foca, K. Vandyck, F. Pauwels, F. Zoulim, D. Durantel. Novel potent capsid assembly modulators regulate multiple steps of the Hepatitis B virus life-cycle. Antimicrobial agents and chemotherapy,  (2018). 

2. J. Lucifora, M. Bonnin, L. Aillot, F. Fusil, S. Maadadi, L. Dimier, M. Michelet, O. Floriot, A. Ollivier, M. Rivoire, M. Ait-Goughoulte, S. Daffis, S. P. Fletcher, A. Salvetti, F. L. Cosset, F. Zoulim, D. Durantel. Direct antiviral properties of TLR ligands against HBV replication in immune-competent hepatocytes. Scientific reports 8, 5390 (2018). 

3. L. Aillot, M. Bonnin, M. Ait-Goughoulte, N. Bendriss-Vermare, S. Maadadi, L. Dimier, M. Subic, C. Scholtes, I. Najera, F. Zoulim, J. Lucifora, D. Durantel. Interaction between Toll-Like Receptor 9-CpG Oligodeoxynucleotides and Hepatitis B Virus Virions Leads to Entry Inhibition in Hepatocytes and Reduction of Alpha Interferon Production by Plasmacytoid Dendritic Cells. Antimicrobial agents and chemotherapy 62,  (2018). 

4. J. Lucifora, A. Salvetti, X. Marniquet, L. Mailly, B. Testoni, F. Fusil, A. Inchauspe, M. Michelet, M. L. Michel, M. Levrero, P. Cortez, T. F. Baumert, F. L. Cosset, C. Challier, F. Zoulim, D. Durantel. Detection of the hepatitis B virus (HBV) covalently-closed-circular DNA (cccDNA) in mice transduced with a recombinant AAV-HBV vector. Antiviral research 145, 14-19 (2017). 

5. A. Diab, A. Foca, F. Fusil, T. Lahlali, P. Jalaguier, F. Amirache, L. N'Guyen, N. Isorce, F. L. Cosset, F. Zoulim, O. Andrisani, D. Durantel. Polo-like-kinase 1 is a proviral host factor for hepatitis B virus replication. Hepatology 66, 1750-1765 (2017). 

6. D. Alfaiate, J. Lucifora, N. Abeywickrama-Samarakoon, M. Michelet, B. Testoni, J. C. Cortay, C. Sureau, F. Zoulim, P. Deny, D. Durantel. HDV RNA replication is associated with HBV repression and interferon-stimulated genes induction in super-infected hepatocytes. Antiviral research 136, 19-31 (2016). 

7. N. Isorce, B. Testoni, M. Locatelli, J. Fresquet, M. Rivoire, S. Luangsay, F. Zoulim, D. Durantel. Antiviral activity of various interferons and pro-inflammatory cytokines in non-transformed cultured hepatocytes infected with hepatitis B virus. Antiviral research 130, 36-45 (2016).

8. S. Luangsay, M. Gruffaz, N. Isorce, B. Testoni, M. Michelet, S. Faure-Dupuy, S. Maadadi, M. Ait-Goughoulte, R. Parent, M. Rivoire, H. Javanbakht, J. Lucifora, D. Durantel*, F. Zoulim*. Early inhibition of hepatocyte innate responses by hepatitis B virus. Journal of hepatology 63, 1314-1322 (2015). 

9. S. Luangsay, M. Ait-Goughoulte, M. Michelet, O. Floriot, M. Bonnin, M. Gruffaz, M. Rivoire, S. Fletcher, H. Javanbakht, J. Lucifora, F. Zoulim*, D. Durantel*. Expression and functionality of Toll- and RIG-like receptors in HepaRG cells. Journal of hepatology 63, 1077-1085 (2015). IF= 12.486

10. B. Jammart, M. Michelet, E. I. Pecheur, R. Parent, B. Bartosch, F. Zoulim, D. Durantel. Very-low-density lipoprotein (VLDL)-producing and hepatitis C virus-replicating HepG2 cells secrete no more lipoviroparticles than VLDL-deficient Huh7.5 cells. Journal of virology 87, 5065-5080 (2013). IF= 4.663

Image d’exemple